# Annual Reportable Labeling Changes for New Drug Applications and Abbreviated New Drug Applications for Nonprescription Drug Products - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/annual-reportable-labeling-changes-for-new-drug-applications-and-abbreviated-new-drug-applications-for-nonprescription-drug-products/d9b364f3-3dda-4016-b1bb-5c4149f0f32b

> FDA guidance document: Annual Reportable Labeling Changes for New Drug Applications and Abbreviated New Drug Applications for Nonprescription Drug Products. Issue date: March 13, 2024. Get complete insights and analysis.

---

## Details

- Title: Annual Reportable Labeling Changes for New Drug Applications and Abbreviated New Drug Applications for Nonprescription Drug Products
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2024-03-13
- Comment Close Date: 2024-05-13
- Last Changed: 2024-03-13
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2023-D-5616">FDA-2023-D-5616</a>

## Related Documents

- [Content and Format of Composition Statement and Corresponding Statement of Ingredients in Labeling in NDAs and ANDAs](https://www.globalkeysolutions.net/guidances/guidance-document/content-and-format-of-composition-statement-and-corresponding-statement-of-ingredients-in-labeling-in-ndas-and-andas/a430f093-c9f8-4001-aef8-771d98ffdbf0)
- [In Vitro Release Test Studies for Topical Drug Products Submitted in ANDAs](https://www.globalkeysolutions.net/guidances/guidance-document/in-vitro-release-test-studies-for-topical-drug-products-submitted-in-andas/c7ff8356-0869-42f7-a5dc-76e32fe0380b)
- [Innovative Approaches for Nonprescription Drug Products](https://www.globalkeysolutions.net/guidances/guidance-document/innovative-approaches-for-nonprescription-drug-products/212b0dcc-7c8f-44f5-8fd2-1af604a50f9a)